Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of Allogeneic NK Cells for Cancer Immunotherapy
Melissa A. Geller, Jeffrey S. Miller
Immunotherapy (2011) Vol. 3, Iss. 12, pp. 1445-1459
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li, David Hermanson, Branden S. Moriarity, et al.
Cell stem cell (2018) Vol. 23, Iss. 2, pp. 181-192.e5
Open Access | Times Cited: 784
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani, Rayne H. Rouce, Enli Liu, et al.
Molecular Therapy (2017) Vol. 25, Iss. 8, pp. 1769-1781
Open Access | Times Cited: 390
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Jing Ni, Matthias Miller, Ana Stojanovic, et al.
The Journal of Experimental Medicine (2012) Vol. 209, Iss. 13, pp. 2351-2365
Open Access | Times Cited: 372
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang, Michael C. Burger, Lukas Jennewein, et al.
JNCI Journal of the National Cancer Institute (2015) Vol. 108, Iss. 5
Open Access | Times Cited: 346
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld, Christiane Sahm, Congcong Zhang, et al.
Molecular Therapy (2014) Vol. 23, Iss. 2, pp. 330-338
Open Access | Times Cited: 311
Engineering the next generation of cell-based therapeutics
Caleb J. Bashor, Isaac B. Hilton, Hozefa S. Bandukwala, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 655-675
Open Access | Times Cited: 254
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation
Nirali N. Shah, Kristin Baird, Cynthia Delbrook, et al.
Blood (2014) Vol. 125, Iss. 5, pp. 784-792
Open Access | Times Cited: 216
Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl, Adelheid Cerwenka
Immunobiology (2015) Vol. 222, Iss. 1, pp. 11-20
Closed Access | Times Cited: 184
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Kyle B. Lupo, Sandro Matosevic
Cancers (2019) Vol. 11, Iss. 6, pp. 769-769
Open Access | Times Cited: 167
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape
Seung Geun Song, Sehui Kim, Jaemoon Koh, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 7, pp. 2035-2048
Closed Access | Times Cited: 113
Cell therapies in the clinic
Liwen Wang, Morgan E. Janes, Ninad Kumbhojkar, et al.
Bioengineering & Translational Medicine (2021) Vol. 6, Iss. 2
Open Access | Times Cited: 110
NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
Ariane Thielens, Éric Vivier, François Romagné
Current Opinion in Immunology (2012) Vol. 24, Iss. 2, pp. 239-245
Open Access | Times Cited: 200
Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
Tolga Sütlü, Sanna Nyström, Mari Gilljam, et al.
Human Gene Therapy (2012) Vol. 23, Iss. 10, pp. 1090-1100
Open Access | Times Cited: 141
Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Yaewon Yang, Okjae Lim, Tae Min Kim, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 3, pp. 215-224
Open Access | Times Cited: 133
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Qing Zhang, Haixu Zhang, Jiage Ding, et al.
Journal of Immunology Research (2018) Vol. 2018, pp. 1-11
Open Access | Times Cited: 131
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Meriem Hasmim, Yosra Messai, Linda Ziani, et al.
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 126
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
Folashade Otegbeye, Evelyn Ojo, Stephen Moreton, et al.
PLoS ONE (2018) Vol. 13, Iss. 1, pp. e0191358-e0191358
Open Access | Times Cited: 121
Next-generation cell therapies: the emerging role of CAR-NK cells
Rafet Başar, May Daher, Katayoun Rezvani
Blood Advances (2020) Vol. 4, Iss. 22, pp. 5868-5876
Open Access | Times Cited: 108
Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
Mao Lin, Haihua Luo, Shuzhen Liang, et al.
Journal of Clinical Investigation (2020) Vol. 130, Iss. 5, pp. 2560-2569
Open Access | Times Cited: 105
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
Jesus I. Luna, Steven K. Grossenbacher, William J. Murphy, et al.
Expert Opinion on Biological Therapy (2016) Vol. 17, Iss. 3, pp. 313-324
Open Access | Times Cited: 90
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Hind Rafei, May Daher, Katayoun Rezvani
British Journal of Haematology (2020) Vol. 193, Iss. 2, pp. 216-230
Open Access | Times Cited: 84
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Hui Lü, Xiaoyan Zhao, Ziying Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 84
Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients
Mao Lin, Xiaoyan Zhang, Shuzhen Liang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 72
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Cristina Zalfa, Silke Paust
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 69
The next wave of cellular immunotherapies in pancreatic cancer
Dannel Yeo, Caroline Giardina, Payal Saxena, et al.
Molecular Therapy — Oncolytics (2022) Vol. 24, pp. 561-576
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top